BB Biotech Revenue vs. Return On Equity
| BBZA Stock | EUR 40.35 0.55 1.38% |
For BB Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BB Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BB Biotech AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BB Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BB Biotech AG over time as well as its relative position and ranking within its peers.
BBZA |
BB Biotech AG Return On Equity vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BB Biotech's current stock value. Our valuation model uses many indicators to compare BB Biotech value to that of its competitors to determine the firm's financial worth. BB Biotech AG is the top company in revenue category among its peers. It also is number one stock in return on equity category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BB Biotech's earnings, one of the primary drivers of an investment's value.BBZA Revenue vs. Competition
BB Biotech AG is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is currently estimated at about 320.04 Billion. BB Biotech has negative revenue of (351.23 Million) contributing less than 1% to the industry.
BBZA Return On Equity vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
BB Biotech |
| = | (351.23 M) |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
BB Biotech |
| = | -0.12 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
BBZA Return On Equity Comparison
BB Biotech is currently under evaluation in return on equity category among its peers.
BBZA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BB Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BB Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BB Biotech's important profitability drivers and their relationship over time.
Use BB Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BB Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BB Biotech will appreciate offsetting losses from the drop in the long position's value.BB Biotech Pair Trading
BB Biotech AG Pair Trading Analysis
The ability to find closely correlated positions to BB Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BB Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BB Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BB Biotech AG to buy it.
The correlation of BB Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BB Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BB Biotech AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BB Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BB Biotech position
In addition to having BB Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Exotic Funds Thematic Idea Now
Exotic Funds
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BBZA Stock
To fully project BB Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BB Biotech AG at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BB Biotech's income statement, its balance sheet, and the statement of cash flows.